Cyber Monday Deal: Up to 60% off InvestingProCLAIM SALE

Becton Dickinson and Company (BDX)

NYSE
Currency in USD
221.26
-1.57(-0.70%)
Closed
After Hours
221.26+0.01(+0.00%)
BDX Scorecard
Full Analysis
Has raised its dividend for 54 consecutive years
Fair Value
Day's Range
221.00222.82
52 wk Range
218.75249.89
Key Statistics
Edit
Prev. Close
222.82
Open
222.82
Day's Range
221-222.82
52 wk Range
218.75-249.89
Volume
1.74M
Average Volume (3m)
1.43M
1-Year Change
-6.48%
Book Value / Share
unlockUnlock
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BDX Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
281.10
Upside
+27.05%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year
Show more

Becton Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation systems, and medication inventory optimization and tracking systems; hemodynamic monitoring systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Becton Dickinson and Company SWOT Analysis


Financial Dynamics
Becton Dickinson reports mixed Q3 results, with EPS beat offset by sales shortfall. Management adjusts organic growth forecast, reflecting market realities.
Strategic Expansion
Explore the impact of Becton Dickinson's acquisition of Edwards Critical Care, potentially adding $0.36 to annual EPS and strengthening market position.
Global Market Challenges
Delve into BDX's navigation of international markets, particularly the headwinds in China, and its implications for the company's global growth strategy.
Future Projections
Analysts estimate BDX's EPS at $13.10 for FY1 and $14.31 for FY2, with management projecting 10% EPS growth and 25%+ margins for FY2025.
Read full SWOT analysis
BDX Full Pro Research
Institutional-Grade Stock Analysis
Understand how BDX earns money
Financial health at a glance
Bearish and bullish outlooks
Latest expert insights
Actionable Pro Tips, and many more...
Gain access to 1400+ in-depth research reports on the most popular US stocks

Becton Dickinson and Company Earnings Call Summary for Q3/2024

  • BD reports 5.2% organic revenue growth in Q3, raises adjusted diluted EPS guidance for fiscal 2024
  • Company projects 10% EPS growth in FY2025, aims to exceed 25% operating margin
  • GLP-1 drug delivery sector expected to reach $1 billion by 2030; over 40 biosimilar agreements signed
  • Transitory challenges in China impact revenue; BD remains optimistic about recovery and growth
  • Strategic focus on innovation and operational simplification drives confidence in future performance
Last Updated: 08/02/2024, 03:22 AM
Read Full Transcript

Compare BDX to Peers and Sector

Metrics to compare
BDX
Peers
Sector
Relationship
P/E Ratio
37.6x18.5x−0.7x
PEG Ratio
2.030.120.00
Price/Book
2.5x2.9x2.6x
Price / LTM Sales
3.2x3.0x3.2x
Upside (Analyst Target)
23.4%16.5%43.2%
Fair Value Upside
Unlock2.7%6.8%Unlock

Analysts' Recommendations

15 Buy
3 Hold
0 Sell
Ratings:
16 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 281.10

(+27.04% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 5.88
Dividend Yield
1.87%
Industry Median 0.73%
Annualized payout
4.1600
Paid quarterly
5-Years Growth
+4.29%
Growth Streak

People Also Watch

247.98
ECL
-0.19%
395.37
SHW
-0.05%
330.60
APD
-1.50%
275.88
ITW
-0.94%
222.65
CTAS
+0.00%

FAQ

What Is the Becton Dickinson (BDX) Stock Price Today?

The Becton Dickinson stock price today is 221.26

What Stock Exchange Does Becton Dickinson Trade On?

Becton Dickinson is listed and trades on the NYSE stock exchange.

What Is the Stock Symbol for Becton Dickinson?

The stock symbol for Becton Dickinson is "BDX."

Does Becton Dickinson Pay Dividends? What’s The Current Dividend Yield?

The Becton Dickinson dividend yield is 1.87%.

What Is the Becton Dickinson Market Cap?

As of today, Becton Dickinson market cap is 64.09B.

What is Becton Dickinson Earnings Per Share?

The Becton Dickinson EPS is 5.88.

What Is the Next Becton Dickinson Earnings Date?

Becton Dickinson will release its next earnings report on Feb 05, 2025.

From a Technical Analysis Perspective, Is BDX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.